Avemar®: Mechanism of Action
Completely stops metastasis when combined with chemotherapy drugs.
Stops metastasis in experimental animals in itself.
Converts cancer cells into healthy cells by the inhibition of the Warburg-effect and by restoring normal metabolism and oxidative mitochondrial activity in cancer cells.
Stops glucose uptake and glucose metabolism in human tumors, while sugar metabolism of healthy cells remains unchanged.
Stops the Warburg-effect in human tumors.
Starts autophagy in human tumors.
Stops the stemness-maintaining mTOR–pentose phosphate pathway (PPP) axis in human colorectal cancer specimens
Blocks PARP: Impairs DNA repair, inducing apoptosis selectively in tumor cells (spares healthy ones).
Inhibition of the stemness-maintaining Wnt/beta-catenin signaling in human ovarian cancer cell lines
Reduces MHC-I: Lowers tumor camouflage, sensitizing cells to Natural Killer cells, killing and curbing metastasis.
Upregulates ICAM-1: Boosts leukocyte infiltration into tumors for better immune attack.
Inhibits RR: Blocks DNA synthesis in hyperactive cancer cells.
Inhibits COX-1/2: Reduces inflammation; supports rheumatoid arthritis adjunct use.
Synergizes with chemo (e.g., cisplatin) via glycolysis/pentose cycle interference.
Avemar has been, so far, the only known natural product which could turn Oct-4 a druggable clinical target.